At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
LEO 152020 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2a Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria
In Brief
A Phase 2 clinical trial evaluating LEO 152020 and LEO 152020 placebo for Cholinergic Urticaria. Completed, enrolled 20 participants across 6 sites.
Detailed Summary
Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with cholinergic urticaria
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholinergic Urticaria
CountriesGermany
CollaboratorsLEO Pharma
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionJul 2022
Study CompletionJul 2022
TodayJul 2026
First PostedApr 22, 2021
Enrollment StartMay 10, 2021
Primary CompletionJul 8, 2022
Study CompletionJul 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.2 years ago
Interventions
LEO 152020drug
LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
LEO 152020 placebodrug
LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.